<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5677">
  <stage>Registered</stage>
  <submitdate>10/03/2014</submitdate>
  <approvaldate>10/03/2014</approvaldate>
  <nctid>NCT02086045</nctid>
  <trial_identification>
    <studytitle>Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial</studytitle>
    <scientifictitle>A NON-RANDOMIZED, CONSECUTIVE ENROLLMENT EVALUATION OF THE DESolve® NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ELX-CL-1003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Artery Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System

Other: DESolve Novolimus Eluting Bioresorbable Coronary Scaffold - DESolve Scaffold


Treatment: devices: DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System
percutaneous coronary

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinically-indicated major adverse cardiac events (MACE) - cardiac death, target vessel MI, clinically indicated TLR</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Late Lumen Loss - MLD post procedure - MLD at follow-up</outcome>
      <timepoint>6 month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Major Adverse Cardiac Events - cardiac death, target vessel MI, clinically indicated TLR</outcome>
      <timepoint>1 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major Adverse Cardiac Events - cardiac death, target vessel MI, clinically indicated TLR</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major Adverse Cardiac Events - cardiac death, target vessel MI, clinically indicated TLR</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major Adverse Cardiac Events - cardiac death, target vessel MI, clinically indicated TLR</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major Adverse Cardiac Events - cardiac death, target vessel MI, clinically indicated TLR</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major Adverse Cardiac Events - cardiac death, target vessel MI, clinically indicated TLR</outcome>
      <timepoint>5 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically-Indicated Target Lesion Failure (TLF) - cardiac death, MI, clinically indicated TLR</outcome>
      <timepoint>1 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically-Indicated Target Lesion Failure (TLF) - cardiac death, MI, clinically indicated TLR</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically-Indicated Target Lesion Failure (TLF) - cardiac death, MI, clinically indicated TLR</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically-Indicated Target Lesion Failure (TLF) - cardiac death, MI, clinically indicated TLR</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically-Indicated Target Lesion Failure (TLF) - cardiac death, MI, clinically indicated TLR</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically-Indicated Target Lesion Failure (TLF) - cardiac death, MI, clinically indicated TLR</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically-Indicated Target Lesion Failure (TLF) - cardiac death, MI, clinically indicated TLR</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically-Indicated Target Vessel Failure (TVF) - cardiac death, MI, clinically indicated TVR</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically-Indicated Target Vessel Failure (TVF) - cardiac death, MI, clinically indicated TLR</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically-Indicated Target Vessel Failure (TVF) - cardiac death, MI, clinically indicated TLR</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically-Indicated Target Vessel Failure (TVF) - cardiac death, MI, clinically indicated TLR</outcome>
      <timepoint>4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically-Indicated Target Vessel Failure (TVF) - cardiac death, MI, clinically indicated TLR</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Scaffold Thrombosis - ARC defined</outcome>
      <timepoint>through 5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patient must be at least 18 years of age and for the 35-patient subset, patients must
             be over the age of 50

          -  Patient is able to verbally confirm understanding of risks, benefits and treatment
             alternatives of receiving the DESolve Nx Novolimus Eluting BCSS and he/she provides
             written informed consent, as approved by the appropriate Ethics Committee of the
             respective clinical site, prior to any clinical study related procedure

          -  Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina,
             silent ischemia, positive functional study or electrocardiogram (ECG) changes
             consistent with ischemia)

          -  Patient must be an acceptable candidate for coronary artery bypass graft (CABG)
             surgery

          -  Patient must agree to undergo all clinical study required follow-up visits,
             angiograms, and as applicable, IVUS, OCT, MSCT and coronary vasomotion testing

          -  Patient must agree not to participate in any other clinical study for a period of two
             years following the index procedure

        Angiographic 

        Target lesion must be located in a native coronary artery with a nominal vessel diameter of
        between 2.75 and 3.5 mm assessed by online QCA

          -  Target lesion must measure = 14 mm in length

          -  Target lesion must be in a major artery or branch with a visually estimated stenosis
             of = 50% and &lt; 90% with a TIMI flow of = 1

          -  Percutaneous intervention of lesions in the target vessel if:

               1. Not part of a clinical investigation

               2. = 6 months prior to the study index procedure

               3. = 9 months after the study index procedure (planned)

               4. Previous intervention was distal to and &gt;10mm from the target lesion</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patient has a known diagnosis of acute myocardial infarction (AMI) within 72 hours
             preceding the index procedure and CK and CK-MB have not returned within normal limits
             at the time of procedure

          -  Patient is currently experiencing clinical symptoms consistent with AMI

          -  Patient requires the use of any rotablator intervention during the index procedure

          -  Patient has current unstable arrhythmias

          -  Patient has a known left ventricular ejection fraction (LVEF) &lt; 30%

          -  Patient has received a heart transplant or any other organ transplant or is on a
             waiting list for any organ transplant

          -  Patient is receiving or scheduled to receive chemotherapy for malignancy within 30
             days prior to or after the procedure

          -  Patient is receiving immunosuppression therapy and has known immunosuppressive or
             autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus
             etc.)

          -  Patient is receiving chronic anticoagulation therapy (e.g., heparin, coumadin) that
             cannot be stopped and restarted according to local hospital standard procedures.

          -  Patient has a known hypersensitivity or contraindication to aspirin, both heparin and
             bivalirudin, both clopidogrel and ticlopidine, Novolimus, PLLA polymers or contrast
             sensitivity that cannot be adequately pre-medicated

          -  Elective surgery is planned within the first 6 months after the procedure that will
             require discontinuing either aspirin or clopidogrel

          -  Patient has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3, a WBC of &lt;
             3,000 cells/mm3, or documented or suspected liver disease.

          -  Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5
             mg/dL, or patient on dialysis)

          -  Patient has a history of bleeding diathesis or coagulopathy or will refuse blood
             transfusions

          -  Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological
             attack (TIA) within the past six months

          -  Patient has had a significant GI or urinary bleed within the past six months

          -  Patient has extensive peripheral vascular disease that precludes safe 6 French sheath
             insertion

          -  Patient has other medical illness (e.g., cancer or congestive heart failure) or known
             history of substance abuse (alcohol, cocaine, heroin etc.) that may cause
             non-compliance with the clinical study plan, confound the data interpretation or is
             associated with a limited life expectancy (i.e., less than one year)

          -  Patient is already participating in another clinical study

          -  Women of childbearing potential who have not undergone surgical sterilization or are
             not post-menopausal (defined as amenorrheic for at least one year) as well as women
             who are pregnant or nursing

          -  Patient is unable to give their consent, is legally incompetent, or is
             institutionalized by virtue of an order issued by the courts or other authority

        Angiographic Exclusion Criteria

          -  Target lesion(s) meets any of the following criteria:

               1. Aorto-ostial location

               2. Left main location

               3. Located within 5 mm of the origin of the LAD or LCX

               4. Located within an arterial or saphenous vein graft or distal to a diseased
                  arterial or saphenous vein graft

               5. Lesion involving a side branch &gt;2mm in diameter or bifurcation

               6. Previous placement of a scaffold proximal to or within 10 mm of the target lesion

               7. Total occlusion (TIMI flow 0), or TIMI flow &lt; 1

               8. Excessive tortuosity proximal to or within the lesion

               9. Angulation (= 45o) proximal to or within the lesion

              10. Calcification moderate or heavy

              11. Previous intervention restenosis

          -  The target vessel contains visible thrombus

          -  Another clinically significant lesion (&gt;40%) is located in the same major epicardial
             vessel as the target lesion

          -  Patient has a high probability that a procedure other than pre-dilatation and
             scaffolding and (if necessary) post-dilatation will be required at the time of index
             procedure for treatment of the target vessel (e.g. atherectomy, cutting balloon or
             brachytherapy)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>126</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>15/05/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerp</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Genk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Uberlandia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aarhus N</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Dabrowa Górnicza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Elixir Medical Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the safety, performance and efficacy of the Elixir DESolve® Novolimus Eluting
      Bioresorbable Coronary Scaffold System (BCSS) in patients with a single de novo native
      coronary artery lesion designated the target lesion and up to one non-target lesion located
      in a separate epicardial vessel.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02086045</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Alex Abizaid, MD, PhD</name>
      <address>Instituto Dante Pazzanese de Cardiologia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>